

Remarks

In the amendments to the specification, Applicant has provided a definition for the word "peptidomimetic" as requested by the Examiner during the telephone interview on May 8, 2007. This definition is known to those in the art, as is supported by the reference Denicourt et al., Science. "Targeting Apoptotic Pathways in Cancer Cells." 2004 Sep 3; 305 (5689):1411-13, 1411. A copy of the reference is enclosed for the Examiner's convenience. Definitions known to those in the art are not new matter. MPEP §2163.07 (reciting "[t]he mere inclusion of dictionary or art recognized definitions known at the time of filing an application would not be considered new matter").


Claim 43 is new; support for this claim may be found in paragraphs 102-105 of the application as published. No new matter has been added by the new claim 43 or the amendments to the claims.

Although Applicant does not believe any fees to be due, the Commissioner for Patents is hereby authorized to charge any deficiency in fees due with the filing of this document and during prosecution of this application to Deposit Account No. 50-0951.

Respectfully submitted,
AKERMAN SENTERFITT

Date: May 18, 2007

Docket No. 4007-009


Blair R. Lanier
Registration No. 56,910
AKERMAN SENTERFITT
P.O. Box 3188
West Palm Beach, FL 33402-3188
Tel: 561-653-5000